Skip to main content

Press Releases

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Date Title
Toggle Summary Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals
Appointment Marks Pyott's Return to Dermatology and Aesthetics WESTLAKE VILLAGE, Calif. , Feb. 28, 2017 /PRNewswire/ --  Sienna Biopharmaceuticals, Inc. , a privately held, clinical-stage medical dermatology and aesthetics company, is pleased to announce that David E.I.
Toggle Summary Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
Seasoned Executive Brings Experience from Medicis and Novan WESTLAKE VILLAGE, Calif. , March 24, 2017 /PRNewswire/ --  Sienna Biopharmaceuticals, Inc. , a privately held, clinical-stage medical dermatology and aesthetics company, today announced that Richard Peterson will join the company as
Toggle Summary Sienna Biopharmaceuticals Acquires Creabilis plc
Acquisition Adds Phase IIb Product, Clinical Candidates and Novel Discovery Platform to Sienna's Growing Pipeline WESTLAKE VILLAGE, Calif. , Dec. 6, 2016 /PRNewswire/ --  Sienna Biopharmaceuticals, Inc. , a privately held, clinical-stage medical dermatology and aesthetics company, today
Toggle Summary Sienna Biopharmaceuticals Announces $34 Million Series A Financing
Company Founded to Improve Patient Outcomes and Advance Practice of Medicine in Aesthetics and Medical Dermatology WESTLAKE VILLAGE, Calif.--( BUSINESS WIRE )--Sienna Biopharmaceuticals, Inc., a development stage company focused on aesthetics and medical dermatology, today announced that it
Toggle Summary Sienna Biopharmaceuticals Announces $40 Million Series B Financing
Topical Biotech Innovation in Medical Dermatology and Aesthetics WESTLAKE VILLAGE, Calif.--( BUSINESS WIRE )-- Sienna Biopharmaceuticals, Inc. , a privately held, clinical stage medical dermatology and aesthetics company, today announced that it completed a $40 million Series B financing led by
Toggle Summary Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WESTLAKE VILLAGE, Calif. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the closing of the Company’s initial public offering of 4,983,333 shares of common stock at a public offering price of $15.00 per share, which includes the exercise in full by
Toggle Summary Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125
-- Trial to Enroll Approximately 15 Patients with Psoriasis -- Top-Line Results Expected in Third Quarter of 2018 WESTLAKE VILLAGE, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed in the Company’s
Toggle Summary Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
-- Trial to Enroll Approximately 190 Patients with Pruritus Associated with Psoriasis -- Top-Line Results Expected in First Half of 2019 WESTLAKE VILLAGE, Calif. , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed
Toggle Summary Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
-- Trial to Enroll Approximately 30 Patients with Atopic Dermatitis -- Top-Line Results Expected in Fourth Quarter of 2018 WESTLAKE VILLAGE, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc.  (NASDAQ:SNNA) today announced that the first patient has been dosed in the
Toggle Summary Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019
-- 27% of subjects achieved 75% reduction in PASI score (PASI 75) vs 13% with vehicle; 29% of subjects achieved two-grade improvement on IGA and ‘clear’ or ‘almost clear’ skin vs 13% with vehicle (statistically significant) -- Subjects achieved 58% improvement in itch from baseline on the I-NRS vs
Toggle Summary Sienna Biopharmaceuticals Announces Pivotal Trials with SNA-001 in Acne Did Not Meet Primary and Secondary Endpoints
-- Results from independent pivotal trials with SNA-001 for the reduction of unwanted light-pigmented hair expected beginning in the fourth quarter of 2018 -- Sienna continues to advance robust multi-asset pipeline, including SNA-120 and SNA-125 -- Company will conduct conference call and webcast
Toggle Summary Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
-- Phase 1/2 study data of SNA-125 in atopic dermatitis on track to be released in fourth quarter of 2018 -- SNA-125 Phase 2 studies expected to begin in second half of 2019 WESTLAKE VILLAGE, Calif. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc.
Toggle Summary Sienna Biopharmaceuticals Announces Second Closing of Series A Financing
Strong Investor Demand Increases Total Investments to $46M WESTLAKE VILLAGE, Calif.--( BUSINESS WIRE )-- Sienna Biopharmaceuticals, Inc. (Sienna), a clinical stage company focused on medical dermatology and aesthetics, today announced it has completed a second closing of its Series A financing,
Toggle Summary Sienna Biopharmaceuticals Appoints Caroline Van Hove as Chief Commercial Officer
-- Expansion of Leadership Team Enables Sienna to Prepare for Commercial Focus with Five Development Programs Now in the Clinic WESTLAKE VILLAGE, Calif. , March 22, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of Caroline Van Hove as the
Toggle Summary Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors
WESTLAKE VILLAGE, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. , a privately held, clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products
Toggle Summary Sienna Biopharmaceuticals Appoints Finance Veteran, James M. Hindman, to Board of Directors
-- Hindman will chair Sienna’s Audit Committee WESTLAKE VILLAGE, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that James (Jim) M. Hindman has been appointed to the Company’s
Toggle Summary Sienna Biopharmaceuticals Appoints John W. Smither as Chief Financial Officer
Richard Peterson Departing for Personal Reasons WESTLAKE VILLAGE, Calif. , March 21, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of John W. Smither as the Company’s Chief Financial Officer. Mr.
Toggle Summary Sienna Biopharmaceuticals Enters $40 Million Term Loan Agreement
WESTLAKE VILLAGE, Calif. , July 02, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the Company has entered a $40 million term loan agreement with Silicon Valley Bank . Sienna drew $30 million on closing. The remaining tranche of $10 million may be drawn
Toggle Summary Sienna Biopharmaceuticals Establishes Corporate Advisory Board
Diverse Panel of Key Opinion Leaders to Share Expertise Across Company’s Therapeutic Focus Areas WESTLAKE VILLAGE, Calif. , Dec. 12, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the formation of a Corporate Advisory Board that will provide scientific,
Toggle Summary Sienna Biopharmaceuticals Reports First Quarter 2018 Financial Results
WESTLAKE VILLAGE, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the first quarter of 2018. “We are pleased to report the results of our first quarter,” said Frederick C.
Toggle Summary Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
-- Pipeline Includes Five Clinical-Stage Programs -- Data from Five Clinical Programs Expected, Beginning in 2H18 WESTLAKE VILLAGE, Calif. , March 15, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the fourth quarter and
Toggle Summary Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results
WESTLAKE VILLAGE, Calif. , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the second quarter of 2017. “We are pleased to report the results of our second quarter,” said Frederick C.
Toggle Summary Sienna Biopharmaceuticals Reports Second Quarter 2018 Financial Results
WESTLAKE VILLAGE, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today reported the Company’s financial results for the second quarter of 2018. “We are pleased to report the results of a busy
Toggle Summary Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results
WESTLAKE VILLAGE, Calif. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the third quarter of 2017. “We are pleased to report the results of our third quarter,” said Frederick C.
Toggle Summary Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
-- SNA-120, a new chemical entity derived from the company’s Topical by Design™ platform, was well tolerated with minimal to no detectable systemic exposure -- Vast majority of psoriasis patients suffer from itch, yet there are no FDA -approved topical therapies for chronic use in itch -- Phase 2b
Toggle Summary Sienna Biopharmaceuticals to Present at BAML Health Care Conference
WESTLAKE VILLAGE, Calif. , May 11, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Bank of America Merrill Lynch Health Care
Toggle Summary Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
WESTLAKE VILLAGE, Calif. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to
Toggle Summary Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
WESTLAKE VILLAGE, Calif. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to participate in a fireside chat at the BMO Capital Markets
Toggle Summary Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference
WESTLAKE VILLAGE, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Cowen and Company 38 th Annual Health Care
Toggle Summary Sienna Biopharmaceuticals to Present at J.P. Morgan Healthcare Conference
WESTLAKE VILLAGE, Calif. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the 36 th Annual J.P.
Toggle Summary Sienna Biopharmaceuticals to Present at Jefferies Healthcare Conference
WESTLAKE VILLAGE, Calif. , May 31, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Jefferies 2018 Global Healthcare Conference,
Toggle Summary Sienna Biopharmaceuticals to Present at JMP Securities Life Science Conference
WESTLAKE VILLAGE, Calif. , June 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the JMP Securities Life Science Conference ,
Toggle Summary Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breaker at the International Investigative Dermatology Congress
WESTLAKE VILLAGE, Calif. , May 16, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that pre-clinical data from the Company’s topical product candidate SNA-125, a novel, selective kinase inhibitor currently in Phase 1/2 proof-of-concept clinical trials for
Toggle Summary Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) today announced the pricing of the Company’s initial public offering of 4,333,333 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts.
Toggle Summary Sienna Biopharmaceuticals® Reports Third Quarter 2018 Financial Results
WESTLAKE VILLAGE, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today reported the Company’s financial results for the third quarter of 2018. “We are pleased to report the results of our third
Toggle Summary Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference
WESTLAKE VILLAGE, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna®, is scheduled to present at the 6 th Annual Dermatology Summit, Sunday, Jan.